• AMBITION monitoring visit in Harare

    Prof. Rati Ndhlovu (AMBITION PI, University of Zimbabwe) chairs a meeting during the first study monitoring visit in October 2018.

  • AMBITION Investigators Meeting (2018)

    Prof. Olivier Lortholary (Institut Pasteur) and Prof. Graeme Meintjes (UCT) enjoy catching up in London in May 2018.

  • AMBITION Investigators’ Meeting (2018)

    Delegates enjoyed two days of discussions and presentations at Woburn House in London.

  • Keeping busy with patient enrolment and care in Uganda

    Sister Jane Frances and Sister Florence prepare AMBITION study drugs at Kiruddu General Hospital, Kampala.

  • AMBITION Site Initiation Visit, Kampala

    The Ugandan AMBITION sites in Kampala and Mbarara opened to recruitment in August 2018.

  • AMBITION Site Initiation Visit, Harare

    The AMBITION site in Harare opened to recruitment in July 2018.

  • AMBITION Site Initiation Visit, Cape Town

    The AMBITION site in Cape Town opened to recruitment in June 2018.

  • AMBITION Investigators’ Meeting (2018)

    Dr. Edward Mpoza (IDI Uganda) and Dr. David Lawrence (LSHTM) share a dish during the second AMBITION Investigators’ Meeting in London, May 2018.

  • AMBITION GCP & Clinical Trials Course, Gaborone

    Delegates from all AMBITION recruiting sites convened in Gaborone in March 2018 for a week of intensive training on Good Clinical Practice and Clinical Trials.

  • AMBITION GCP & Clinical Trials Course (Gaborone)

    Delegates enjoy applying some of the principles learned during the lecture-based sessions from 12-16 March 2018.

  • AMNET Meeting (January 2018)

    Dr. David Meya lends to the discussions in Lilongwe, January 2018.

  • AMNET Meeting (January 2018)

    Members of the AMNET Steering Committee enjoyed an initial face-to-face meeting in January 2018 hosted by UNC Project Malawi in Lilongwe.

  • AMNET Meeting (January 2018)

    Dr. Admire Hlupeni (AMBITION Study Doctor, University of Zimbabwe) presents his situational analysis at the meeting in Lilongwe.

  • AMBITION Health Economics Course (November 2017)

    Delegates from across the AMBITION Consortium convened in Blantyre for an intensive Health Economics course led by Prof. Louis Niessen from LSTM.

  • Site visit to MLW (2017)

    Dr. Henry Mwandumba (PI at MLW in Blantyre) hosts Dr. Nabila Youssouf and Dr. David Lawrence for a site visit, November 2017.

  • AMBITION Investigators’ Meeting (2017)

    Colleagues from across the AMBITION Consortium convened in Gaborone for a kick-off meeting in May 2017.

Home

AMBITION (High Dose AMBISOME on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomised Controlled Non-inferiority Trial) is a four-year project funded at €10M by the European and Developing Countries Clinical Trials Partnership, the Swedish International Development Agency and the DFID/MRC/Wellcome Trust Joint Global Health Trials Fund. It runs from 1 January 2017 – 31 December 2020 across a consortium of six African and five European partners.

The Phase III clinical trial (AMBITION-cm) is the largest clinical trial for HIV-associated cryptococcal meningitis ever to be conducted. Recruitment of 850 patients is underway and will be concluded by June 2020.

A number of other activities run alongside the trial, including economic cost-effectiveness analyses, laboratory-based sub-studies and capacity building events. AMNET (African Meningitis Trials Network) has been established to provide a solid framework to facilitate future clinical trials to investigate urgently-needed novel treatments and diagnostics strategies aimed at reducing the morbidity and mortality due to meningitis in Africa. AMNET will continue to develop well after AMBITION itself is concluded.

AMBITION is co-ordinated by The London School of Hygiene and Tropical Medicine, UK. African collaborating institutions (which are also our recruiting sites) are shown below.

The AMBITION consortium is extremely grateful to the following funders:

…and to Gilead, who has donated the AmBisome for the clinical trial.

 

 

Comments are closed.